Cortexyme, Inc. (NASDAQ:CRTX – Get Free Report)’s stock price crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.80 and traded as high as $1.69. Cortexyme shares last traded at $1.62, with a volume of 2,176,771 shares changing hands.
Cortexyme Price Performance
The firm has a market capitalization of $46.43 million, a P/E ratio of -0.52 and a beta of 1.40. The stock’s 50-day simple moving average is $0.82 and its two-hundred day simple moving average is $0.81.
Cortexyme Company Profile
Cortexyme, Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection.
Further Reading
- Five stocks we like better than Cortexyme
- What Are Trending Stocks? Trending Stocks Explained
- Battle of the Retailers: Who Comes Out on Top?
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- HCA Healthcare: Temporary Setbacks, Long-Term Strength
- What is a buyback in stocks? A comprehensive guide for investors
- MarketBeat Week in Review – 10/28 – 11/1
Receive News & Ratings for Cortexyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cortexyme and related companies with MarketBeat.com's FREE daily email newsletter.
